You just read:

Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma

News provided by

Eisai Inc.

Jan 19, 2018, 08:08 ET